Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “hold” rating restated by stock analysts at Cowen and Company in a research note issued on Tuesday.

PCRX has been the subject of several other research reports. Mizuho restated a “buy” rating and set a $64.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 20th. BMO Capital Markets initiated coverage on shares of Pacira Pharmaceuticals in a research report on Tuesday, June 28th. They set an “underperform” rating and a $36.00 price objective for the company. Wedbush restated an “outperform” rating and set a $105.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a research report on Wednesday, August 10th. Finally, Brean Capital lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $74.00.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 36.81 on Tuesday. The company’s 50-day moving average is $41.61 and its 200 day moving average is $45.35. The firm’s market cap is $1.37 billion. Pacira Pharmaceuticals has a 12 month low of $31.08 and a 12 month high of $80.25.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, August 4th. The company reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.16. The firm had revenue of $69.60 million for the quarter, compared to analysts’ expectations of $67.80 million. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. Pacira Pharmaceuticals’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter last year, the company earned $0.20 EPS. On average, equities research analysts predict that Pacira Pharmaceuticals will post $0.44 earnings per share for the current year.

In related news, CEO David M. Stack sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $45.32, for a total transaction of $679,800.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President James S. Scibetta sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $45.21, for a total transaction of $1,130,250.00. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Legacy Capital Partners Inc. raised its position in shares of Pacira Pharmaceuticals by 0.4% in the second quarter. Legacy Capital Partners Inc. now owns 23,200 shares of the company’s stock valued at $783,000 after buying an additional 100 shares during the last quarter. American Century Companies Inc. raised its position in shares of Pacira Pharmaceuticals by 0.3% in the second quarter. American Century Companies Inc. now owns 66,391 shares of the company’s stock valued at $2,239,000 after buying an additional 206 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Pacira Pharmaceuticals by 0.9% in the second quarter. Nationwide Fund Advisors now owns 23,816 shares of the company’s stock valued at $803,000 after buying an additional 224 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Pacira Pharmaceuticals by 1.3% in the second quarter. DekaBank Deutsche Girozentrale now owns 18,515 shares of the company’s stock valued at $704,000 after buying an additional 235 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Pacira Pharmaceuticals by 8.5% in the second quarter. US Bancorp DE now owns 5,010 shares of the company’s stock valued at $169,000 after buying an additional 394 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.